Current main theme: Development of nanotherapeutics for the treatment of brin tumors
Glioblastoma (GBM) is the most malignant form of brain tumor. Patients die from relapse of the tumor after surgery, radiotherapy and chemotherapy. Current treatments for GBM have very low efficacy due to their incapacity to cross the blood-brain barrier (BBB) and to eliminate resilient cancers stem cells.
The goal of this highly interdisciplinary project is to develop nanotherapeutics capable of overcoming the BBB and of eliminating all tumor cells, including cancer stem cells. We are interested in developing ligands to target the nanocarrier systems and to cross the BBB. We also aim to engineer polymeric coatings to enhance the stability of the nanocarriers for gene delivery.
Distinct aspects of this ambitious project are funded by "La Caixa", the Spanish Ministry of Science, and the "Asociación Española Contra el Cáncer" (AECC).
Development of stimulus sensitive antibodies
We are engineering new strategies to render antibodies responsive to stimuli and enhance the selectivity of nanotherapeutics.
Generation of new protease-resistant peptide therapeutics and targeting ligands
Our team is developing new efficient peptides that enable the transport of therapeutics across the blood-brain barrier. We are also working on therapeutic peptides for other applications.
Phage display engineering
We aim to develop new peptide and protein therapeutics via directed evolution by expanding the chemical diversity encoded into phage displayed molecules.
Peptide-based smart coatings and gene delivery systems
We utilize peptides to construct materials to construct environmentally-sensitive nanocarriers and coatings.